Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis.

Canagliflozin was associated with a potential 14% reduction in respiratory cancer risk (RR: 0.86, 95% CI: 0.54, 1.38; I2 = 0%), while Empagliflozin showed a trend toward an increased risk compared with placebo (RR: 1.33, 95% CI: 0.70, 2.51; I2 = 0%).

also in 53,322 other papers

Dapagliflozin, on the other hand, suggested a possible trend toward lowering the incidence of respiratory system malignancies, while statistical significance remained elusive.

also in 1,410 other papers